1. Home
  2. CRSP vs CNXC Comparison

CRSP vs CNXC Comparison

Compare CRSP & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • CNXC
  • Stock Information
  • Founded
  • CRSP 2013
  • CNXC 1991
  • Country
  • CRSP Switzerland
  • CNXC United States
  • Employees
  • CRSP N/A
  • CNXC N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • CNXC Computer Software: Prepackaged Software
  • Sector
  • CRSP Health Care
  • CNXC Technology
  • Exchange
  • CRSP Nasdaq
  • CNXC Nasdaq
  • Market Cap
  • CRSP 4.1B
  • CNXC 4.9B
  • IPO Year
  • CRSP 2016
  • CNXC N/A
  • Fundamental
  • Price
  • CRSP $44.62
  • CNXC $72.68
  • Analyst Decision
  • CRSP Buy
  • CNXC Buy
  • Analyst Count
  • CRSP 19
  • CNXC 4
  • Target Price
  • CRSP $74.38
  • CNXC $94.75
  • AVG Volume (30 Days)
  • CRSP 989.9K
  • CNXC 300.2K
  • Earning Date
  • CRSP 08-05-2024
  • CNXC 09-25-2024
  • Dividend Yield
  • CRSP N/A
  • CNXC 1.67%
  • EPS Growth
  • CRSP N/A
  • CNXC N/A
  • EPS
  • CRSP N/A
  • CNXC 4.23
  • Revenue
  • CRSP $202,227,000.00
  • CNXC $8,647,060,000.00
  • Revenue This Year
  • CRSP N/A
  • CNXC $38.09
  • Revenue Next Year
  • CRSP $461.06
  • CNXC $3.15
  • P/E Ratio
  • CRSP N/A
  • CNXC $17.18
  • Revenue Growth
  • CRSP 18.89
  • CNXC 33.62
  • 52 Week Low
  • CRSP $37.55
  • CNXC $53.89
  • 52 Week High
  • CRSP $91.10
  • CNXC $106.10
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 35.02
  • CNXC 57.88
  • Support Level
  • CRSP $46.86
  • CNXC $73.17
  • Resistance Level
  • CRSP $48.27
  • CNXC $76.12
  • Average True Range (ATR)
  • CRSP 1.80
  • CNXC 2.45
  • MACD
  • CRSP -0.11
  • CNXC 0.32
  • Stochastic Oscillator
  • CRSP 16.42
  • CNXC 59.74

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About CNXC Concentrix Corporation

Concentrix Corp is a technology-enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five primary industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Canada, Germany, Great Britain and others.

Share on Social Networks: